Literature DB >> 8650264

DNA-dependent protein kinase defects are linked to deficiencies in DNA repair and V(D)J recombination.

N J Finnie1, T M Gottlieb, T Blunt, P A Jeggo, S P Jackson.   

Abstract

DNA-dependent protein kinase is a nuclear serine/threonine kinase whose catalytic properties are expressed only when the enzyme is bound to DNA ends or other discontinuities in the DNA. DNA-PK comprises two components: one mediates binding to DNA and corresponds to the heterodimeric human autoimmune antigen Ku; the other, DNA-PK catalytic subunit (DNA-PKcs), is a polypeptide of approximately 450 kDa. DNA-PK deficiencies are associated with certain mutant rodent cell lines that display defects in DNA double strand break repair and V(D)J recombination. Specifically, hamster xrs-6 cells lack Ku function, whereas murine scid and hamster V3 cells lack functional DNA-PKcs. Furthermore, the phenotypes of xrs-6 and V3 cells can be corrected by the expression of the genes encoding the 80 kDa component of Ku or DNA-PKcs, respectively. These results imply that DNA-PK is an important component of the DNA double strand break repair/recombination apparatus. Possible roles for DNA-PK in these processes are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8650264     DOI: 10.1098/rstb.1996.0014

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  11 in total

1.  Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line.

Authors:  Elham S Mohammadi; Elizabeth A Ketner; David C Johns; Gary Ketner
Journal:  Nucleic Acids Res       Date:  2004-05-11       Impact factor: 16.971

2.  Molecular and biochemical characterization of xrs mutants defective in Ku80.

Authors:  B K Singleton; A Priestley; H Steingrimsdottir; D Gell; T Blunt; S P Jackson; A R Lehmann; P A Jeggo
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

3.  A central region of Ku80 mediates interaction with Ku70 in vivo.

Authors:  R B Cary; F Chen; Z Shen; D J Chen
Journal:  Nucleic Acids Res       Date:  1998-02-15       Impact factor: 16.971

Review 4.  Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases.

Authors:  Iurii Koboziev; Yava Jones-Hall; John F Valentine; Cynthia Reinoso Webb; Kathryn L Furr; Matthew B Grisham
Journal:  Inflamm Bowel Dis       Date:  2015-07       Impact factor: 5.325

5.  Both V(D)J recombination and radioresistance require DNA-PK kinase activity, though minimal levels suffice for V(D)J recombination.

Authors:  L J Kienker; E K Shin; K Meek
Journal:  Nucleic Acids Res       Date:  2000-07-15       Impact factor: 16.971

6.  KARP-1: a novel leucine zipper protein expressed from the Ku86 autoantigen locus is implicated in the control of DNA-dependent protein kinase activity.

Authors:  K Myung; D M He; S E Lee; E A Hendrickson
Journal:  EMBO J       Date:  1997-06-02       Impact factor: 11.598

7.  DNA looping by Ku and the DNA-dependent protein kinase.

Authors:  R B Cary; S R Peterson; J Wang; D G Bear; E M Bradbury; D J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

8.  Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse.

Authors:  T Blunt; D Gell; M Fox; G E Taccioli; A R Lehmann; S P Jackson; P A Jeggo
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

9.  Human xenografts are not rejected in a naturally occurring immunodeficient porcine line: a human tumor model in pigs.

Authors:  Matthew T Basel; Sivasai Balivada; Amanda P Beck; Maureen A Kerrigan; Marla M Pyle; Jack C M Dekkers; Carol R Wyatt; Robert R R Rowland; David E Anderson; Stefan H Bossmann; Deryl L Troyer
Journal:  Biores Open Access       Date:  2012-04

Review 10.  Humanized Mice as Unique Tools for Human-Specific Studies.

Authors:  Kylie Su Mei Yong; Zhisheng Her; Qingfeng Chen
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2018-02-07       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.